Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Thomann R [verfasserIn] Zechmann S [verfasserIn] Alexander-David N [verfasserIn] Jornayvaz FR [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	insulin glargine 300 u/ml type 2 diabetes real-world switzerland

Übergeordnetes Werk:	In: Diabetes, Metabolic Syndrome and Obesity - Dove Medical Press, 2009, (2020), Seite 2359-2365
Übergeordnetes Werk:	year:2020 ; pages:2359-2365

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ076143392

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ076143392
003	DE-627
005	20230503061946.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ076143392
035			\|a (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-951
100	0		\|a Thomann R \|e verfasserin \|4 aut
245	1	0	\|a Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland
650		4	\|a insulin glargine 300 u/ml
650		4	\|a type 2 diabetes
650		4	\|a real-world
650		4	\|a switzerland
653		0	\|a Specialties of internal medicine
700	0		\|a Zechmann S \|e verfasserin \|4 aut
700	0		\|a Alexander-David N \|e verfasserin \|4 aut
700	0		\|a Jornayvaz FR \|e verfasserin \|4 aut
773	0	8	\|i In \|t Diabetes, Metabolic Syndrome and Obesity \|d Dove Medical Press, 2009 \|g (2020), Seite 2359-2365 \|w (DE-627)60030597X \|w (DE-600)2494854-8 \|x 11787007 \|7 nnns
773	1	8	\|g year:2020 \|g pages:2359-2365
856	4	0	\|u https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-7007 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2020 \|h 2359-2365

Indexfelder

author_variant	t r tr z s zs a d n adn j f jf
matchkey_str	article:11787007:2020----::elolefcieesfnuigagn30nta
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc DE-627 ger DE-627 rakwb eng RC581-951 Thomann R verfasserin aut Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine Zechmann S verfasserin aut Alexander-David N verfasserin aut Jornayvaz FR verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 2359-2365 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:2359-2365 https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc kostenfrei https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 2359-2365
spelling	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc DE-627 ger DE-627 rakwb eng RC581-951 Thomann R verfasserin aut Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine Zechmann S verfasserin aut Alexander-David N verfasserin aut Jornayvaz FR verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 2359-2365 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:2359-2365 https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc kostenfrei https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 2359-2365
allfields_unstemmed	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc DE-627 ger DE-627 rakwb eng RC581-951 Thomann R verfasserin aut Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine Zechmann S verfasserin aut Alexander-David N verfasserin aut Jornayvaz FR verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 2359-2365 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:2359-2365 https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc kostenfrei https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 2359-2365
allfieldsGer	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc DE-627 ger DE-627 rakwb eng RC581-951 Thomann R verfasserin aut Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine Zechmann S verfasserin aut Alexander-David N verfasserin aut Jornayvaz FR verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 2359-2365 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:2359-2365 https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc kostenfrei https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 2359-2365
allfieldsSound	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc DE-627 ger DE-627 rakwb eng RC581-951 Thomann R verfasserin aut Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine Zechmann S verfasserin aut Alexander-David N verfasserin aut Jornayvaz FR verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2020), Seite 2359-2365 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2020 pages:2359-2365 https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc kostenfrei https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 2359-2365
language	English
source	In Diabetes, Metabolic Syndrome and Obesity (2020), Seite 2359-2365 year:2020 pages:2359-2365
sourceStr	In Diabetes, Metabolic Syndrome and Obesity (2020), Seite 2359-2365 year:2020 pages:2359-2365
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	insulin glargine 300 u/ml type 2 diabetes real-world switzerland Specialties of internal medicine
isfreeaccess_bool	true
container_title	Diabetes, Metabolic Syndrome and Obesity
authorswithroles_txt_mv	Thomann R @@aut@@ Zechmann S @@aut@@ Alexander-David N @@aut@@ Jornayvaz FR @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	60030597X
id	DOAJ076143392
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ076143392</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503061946.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ076143392</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Thomann R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, Fran&ccedil;ois R Jornayvaz4 1B&uuml;rgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4H&ocirc;pitaux Universitaires de Gen&egrave;ve, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: Fran&ccedil;ois R JornayvazH&ocirc;pitaux Universitaires de Gen&egrave;ve, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo&reg;) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5&ndash; 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p&lt; 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p&lt; 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">insulin glargine 300 u/ml</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">type 2 diabetes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">real-world</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">switzerland</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zechmann S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander-David N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jornayvaz FR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 2359-2365</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:2359-2365</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">2359-2365</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Thomann R
spellingShingle	Thomann R misc RC581-951 misc insulin glargine 300 u/ml misc type 2 diabetes misc real-world misc switzerland misc Specialties of internal medicine Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
authorStr	Thomann R
ppnlink_with_tag_str_mv	@@773@@(DE-627)60030597X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-951
illustrated	Not Illustrated
issn	11787007
topic_title	RC581-951 Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland insulin glargine 300 u/ml type 2 diabetes real-world switzerland
topic	misc RC581-951 misc insulin glargine 300 u/ml misc type 2 diabetes misc real-world misc switzerland misc Specialties of internal medicine
topic_unstemmed	misc RC581-951 misc insulin glargine 300 u/ml misc type 2 diabetes misc real-world misc switzerland misc Specialties of internal medicine
topic_browse	misc RC581-951 misc insulin glargine 300 u/ml misc type 2 diabetes misc real-world misc switzerland misc Specialties of internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Diabetes, Metabolic Syndrome and Obesity
hierarchy_parent_id	60030597X
hierarchy_top_title	Diabetes, Metabolic Syndrome and Obesity
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)60030597X (DE-600)2494854-8
title	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
ctrlnum	(DE-627)DOAJ076143392 (DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc
title_full	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
author_sort	Thomann R
journal	Diabetes, Metabolic Syndrome and Obesity
journalStr	Diabetes, Metabolic Syndrome and Obesity
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	2359
author_browse	Thomann R Zechmann S Alexander-David N Jornayvaz FR
class	RC581-951
format_se	Elektronische Aufsätze
author-letter	Thomann R
author2-role	verfasserin
title_sort	real-world effectiveness of insulin glargine 300 initiation in switzerland
callnumber	RC581-951
title_auth	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
abstract	Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland
abstractGer	Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland
abstract_unstemmed	Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, François R Jornayvaz4 1Bürgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4Hôpitaux Universitaires de Genève, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: François R JornayvazHôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5– 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p< 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p< 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
url	https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO https://doaj.org/toc/1178-7007
remote_bool	true
author2	Zechmann S Alexander-David N Jornayvaz FR
author2Str	Zechmann S Alexander-David N Jornayvaz FR
ppnlink	60030597X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC581-951
up_date	2024-07-03T18:50:29.913Z
_version_	1803584934948896768
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ076143392</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503061946.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ076143392</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa5a0f4f0a7b346c38eb61152ac5c83cc</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Thomann R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Robert Thomann,1 Stefan Zechmann,2 Nicola Alexander-David3,&dagger;, Fran&ccedil;ois R Jornayvaz4 1B&uuml;rgerspital Solothurn, Solothurn, Switzerland; 2Institute of Primary Care, University of Zurich, Zurich, Switzerland; 3Private Practice, Bellinzona, Switzerland; 4H&ocirc;pitaux Universitaires de Gen&egrave;ve, Geneva, Switzerland&dagger;Nicola Alexander-David passed away on March 02, 2020Correspondence: Fran&ccedil;ois R JornayvazH&ocirc;pitaux Universitaires de Gen&egrave;ve, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, SwitzerlandEmail francois.jornayvazhcuge.chIntroduction: Insulin glargine 300 U/mL (Gla-300; Toujeo&reg;) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5&ndash; 10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety.Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p&lt; 0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p&lt; 0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population.Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.Keywords: insulin glargine 300 U/mL, type 2 diabetes, real-world, Switzerland</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">insulin glargine 300 u/ml</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">type 2 diabetes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">real-world</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">switzerland</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zechmann S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander-David N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jornayvaz FR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 2359-2365</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:2359-2365</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a5a0f4f0a7b346c38eb61152ac5c83cc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/real-world-effectiveness-of-insulin-glargine-300-initiation-in-switzer-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">2359-2365</subfield></datafield></record></collection>
score	7.4005013

Nicht das Richtige dabei?

Schreiben Sie uns!

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?